Condition (MeSH)
Hereditary Sensory and Autonomic Neuropathies
ClinicalTrials.gov lists 185 trials for Hereditary Sensory and Autonomic Neuropathies or a narrower condition beneath it. Novartis Pharmaceuticals has the most among industry and government lead sponsors, with 12.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
1 more section with rows
174 of the 185 trials are tagged with Hereditary Sensory and Autonomic Neuropathies itself; the rest are tagged with a narrower condition beneath it.
When did Hereditary Sensory and Autonomic Neuropathies trials start? (23)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 15
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 9 |
| 2025 | 9 |
| 2024 | 15 |
| 2023 | 8 |
| 2022 | 12 |
| 2021 | 12 |
| 2020 | 12 |
| 2019 | 10 |
| 2018 | 12 |
| 2017 | 10 |
Showing 10 of 23 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 12 trials starting in 2026 and about 11 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 36 months from start to primary completion across 25 trials still running at the 2026-10-09 snapshot; registered median of 28 months across 116 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hereditary Sensory and Autonomic Neuropathies trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 31 |
| Phase 1/2 | 25 |
| Phase 2 | 48 |
| Phase 2/3 | 5 |
| Phase 3 | 17 |
| Phase 4 | 7 |
| Not applicable | 23 |
| Observational | 28 |
| Expanded access | 1 |
How many Hereditary Sensory and Autonomic Neuropathies trials are recruiting? (10)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 6 |
| Recruiting | 29 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 11 |
| Completed | 83 |
Showing 5 of 10 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hereditary Sensory and Autonomic Neuropathies trials? (10)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Novartis Pharmaceuticals | 12 |
| Pfizer | 9 |
| AstraZeneca | 7 |
| Cascadian Therapeutics Inc. | 3 |
| EMD Serono Research & Development Institute, Inc. | 3 |
Showing 5 of 10 sponsors.
Which drugs are being tested for Hereditary Sensory and Autonomic Neuropathies? (10)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| FULVESTRANT | 8 |
| EVEROLIMUS | 6 |
| CETUXIMAB | 5 |
| Nerve Growth Factor | 5 |
| Sirolimus | 5 |
Showing 5 of 10 drugs.
Interventions as named in the registry (5)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Alpelisib Pill | 8 |
| Tanezumab SC | 7 |
| Letrozol (Femara, Novartis) | 4 |
| Palbociclib Pill | 3 |
| BKM120 | 3 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Hereditary Sensory and Autonomic Neuropathies trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pneumonia | 113 | 21 |
| Diarrhoea | 86 | 18 |
| Dyspnoea | 71 | 16 |
| Osteoarthritis | 62 | 4 |
| Neutropenia | 61 | 5 |
Showing 5 of 10 adverse events.
Which publications cover Hereditary Sensory and Autonomic Neuropathies? (9)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Randomized trial of l-serine in patients with hereditary sensory and autonomic neuropathy type 1. | Neurology | 2019 | Yes |
| Assessment of patients with hereditary transthyretin amyloidosis - understanding the impact of management and disease progression. | Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis | 2019 | Yes |
| Fenofibrate lowers atypical sphingolipids in plasma of dyslipidemic patients: A novel approach for treating diabetic neuropathy? | Journal of clinical lipidology | 2015 | Yes |
| Oral L-serine supplementation reduces production of neurotoxic deoxysphingolipids in mice and humans with hereditary sensory autonomic neuropathy type 1. | The Journal of clinical investigation | 2011 | Yes |
| Autosomal recessive spastic paraplegia (SPG30) with mild ataxia and sensory neuropathy maps to chromosome 2q37.3. | Brain : a journal of neurology | 2006 | Yes |
Showing 5 of 9 publications.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Hereditary sensory and autonomic neuropathy | 140471 | Exact | Orphadata Science knowledge files, Product 1 |
| Hereditary sensory and autonomic neuropathy | 140471 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence.